| Name | Title | Contact Details |
|---|
Inspectis Digital Microscopes are elegant solutions for modern optical inspection tasks. We manufacture carefully specified Optical Systems for optimum performance, sleekly designed and made from durable high quality materials making them fit for purpose of a long life in real working environments.
Synonym is accelerating the worlds biological future by developing, financing and building commercial-scale biomanufacturing facilities. We provide synthetic biology (synbio) producers – from startups to the Fortune 500 – with flexible production capacity while giving infrastructure investors access to a new, carbon-negative biomanufacturing asset class that we are calling "fermentation farms".
Arkeyo offers self-service coin counting / cash dispensing kiosks to banks, casinos, grocery stores and other retail locations. Arkeyo is delivering high profile products and services designed to engage and efficiently monetize the growing need for a new self-service coin alternative in the USA and Europe. Clients can select from a full set of product lines, in their own language and their own currency. Arkeyo also picks up and processes coin bins and coin bags. Unlike legacy self-service coin offerings, Arkeyo gives retailers powerful tools to narrowcast their direct marketing, to identify and engage the right customer with the right offering at the right time, enhancing results and efficiency. Rules-based intelligence, routing and reporting tools offer retailers the opportunity to increase sales, lower customer service costs, shorten ‘float time and encourage repeat business. Through an affiliate program, users of the self-service coin machines can earn credit toward future purchases and exchange points with offline affiliate partners.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.